Clinical Trial Results:
A Randomized, Placebo-controlled, Double-blind, Multi-center, Phase 2 Study to Assess the Efficacy and Safety of CNTO 6785 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
Summary
|
|
EudraCT number |
2012-003607-36 |
Trial protocol |
CZ DE HU |
Global end of trial date |
28 Sep 2015
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
08 Jul 2016
|
First version publication date |
08 Jul 2016
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
CNTO6785OPD2001
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT01966549 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
JanssenCilag International NV
|
||
Sponsor organisation address |
Turnhoutseweg 30, Beerse, Belgium, 2340
|
||
Public contact |
Clinical Registry Group, JanssenCilag International NV, ClinicalTrialsEU@its.jnj.com
|
||
Scientific contact |
Clinical Registry Group, JanssenCilag International NV, ClinicalTrialsEU@its.jnj.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
28 Sep 2015
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
28 Sep 2015
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The main objective of this study was to assess the efficacy of CNTO 6785 compared with placebo in subjects with symptomatic Global Initiative for Chronic Obstructive Lung Disease (GOLD) Grade II and GOLD Grade III COPD.
|
||
Protection of trial subjects |
To protect the subjects in the study, a series of risk management actions were considered, excluding subjects with potential risks entering into the study, designed the discontinuation criteria during the study, applying for the comprehensive medical monitoring of clinical data on an ongoing basis and an independent Data Monitoring Committee to review unblinded data during the study to monitor patient safety and provide recommendation to the study implementation when identify significant safety signals. Safety monitoring also include assessing adverse Events, brief physical examinations, vital signs measurements, electrocardiogram (ECG) measurements, signs and symptoms of active tuberculosis (TB), laboratory assessments including chemistry, hematology and urinalysis during the study.
|
||
Background therapy |
Subjects received Inhalation of long acting bronchodilators. | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
11 Nov 2013
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Czech Republic: 53
|
||
Country: Number of subjects enrolled |
Germany: 55
|
||
Country: Number of subjects enrolled |
Hungary: 21
|
||
Country: Number of subjects enrolled |
Korea, Republic of: 13
|
||
Country: Number of subjects enrolled |
Malaysia: 9
|
||
Country: Number of subjects enrolled |
Poland: 15
|
||
Country: Number of subjects enrolled |
Russian Federation: 19
|
||
Country: Number of subjects enrolled |
Taiwan: 2
|
||
Worldwide total number of subjects |
187
|
||
EEA total number of subjects |
144
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
116
|
||
From 65 to 84 years |
71
|
||
85 years and over |
0
|
|
|||||||||||||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||||||||||||
Recruitment details |
A total of 187 male and female subjects with moderate to severe COPD subjects despite inhaled long acting bronchodilators with or without inhaled corticosteroids were enrolled and and randomized equally to the placebo and CNTO 6785 group. | ||||||||||||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||||||||||||
Screening details |
The study consisted of Screening phase (Week -3 to immediately prior to randomization at Study Visit 3), Treatment phase (at Study Visit 3 through Study Visit 8 at Week 12) and follow-up phase (after Study Visit 8 through Week 24). Prior to enrollment, subjects were screened to assess their eligibility for participation in the study. | ||||||||||||||||||||||||||||||
Period 1
|
|||||||||||||||||||||||||||||||
Period 1 title |
Overall Study (overall period)
|
||||||||||||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||||||||||||||
Roles blinded |
Subject, Investigator, Carer | ||||||||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||||||||
Arm title
|
Placebo | ||||||||||||||||||||||||||||||
Arm description |
Subjects received intravenous (IV) infusion of placebo (for not less than 30 minutes in duration) at Week 0, 2, 4, 8 and 12. | ||||||||||||||||||||||||||||||
Arm type |
Placebo | ||||||||||||||||||||||||||||||
Investigational medicinal product name |
Placebo
|
||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||
Pharmaceutical forms |
Infusion
|
||||||||||||||||||||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||||||||||||||||||||
Dosage and administration details |
Subjects received placebo IV infusion at Week 0, 2, 4, 8 and 12.
|
||||||||||||||||||||||||||||||
Arm title
|
CNTO 6785 | ||||||||||||||||||||||||||||||
Arm description |
Subjects received IV infusion (for not less than 30 minutes in duration) of CNTO 6785 6 milligram per kilogram (mg/kg) at Week 0, 2, 4, 8 and 12. | ||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||
Investigational medicinal product name |
CNTO 6785
|
||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||
Pharmaceutical forms |
Infusion
|
||||||||||||||||||||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||||||||||||||||||||
Dosage and administration details |
Subjects received CNTO 6785 6 mg/kg IV infusion at Week 0, 2, 4, 8 and 12.
|
||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received intravenous (IV) infusion of placebo (for not less than 30 minutes in duration) at Week 0, 2, 4, 8 and 12. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
CNTO 6785
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received IV infusion (for not less than 30 minutes in duration) of CNTO 6785 6 milligram per kilogram (mg/kg) at Week 0, 2, 4, 8 and 12. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Placebo
|
||
Reporting group description |
Subjects received intravenous (IV) infusion of placebo (for not less than 30 minutes in duration) at Week 0, 2, 4, 8 and 12. | ||
Reporting group title |
CNTO 6785
|
||
Reporting group description |
Subjects received IV infusion (for not less than 30 minutes in duration) of CNTO 6785 6 milligram per kilogram (mg/kg) at Week 0, 2, 4, 8 and 12. |
|
|||||||||||||||||||
End point title |
Change From Baseline in Prebronchodilator Percent-Predicted Forced Expiratory Volume in 1 Second (FEV1) at Week 16 | ||||||||||||||||||
End point description |
FEV1 is the amount of air that can be exhaled in one second. FEV1 was measured by spirometry. A positive change from baseline in FEV1 indicates improvement in lung function. Modified intent-to-treat (mITT) analysis set included subjects who received at least 1 or partial dose of study agent and had at least 1 post-treatment efficacy measurement.
|
||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||
End point timeframe |
Baseline and Week 16
|
||||||||||||||||||
|
|||||||||||||||||||
Notes [1] - Here "N" signifies number of subjects analysed for this endpoint. [2] - Here "N" signifies number of subjects analysed for this endpoint. |
|||||||||||||||||||
Statistical analysis title |
Statistical Analysis | ||||||||||||||||||
Comparison groups |
CNTO 6785 v Placebo
|
||||||||||||||||||
Number of subjects included in analysis |
185
|
||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||
Analysis type |
superiority | ||||||||||||||||||
P-value |
= 0.599 | ||||||||||||||||||
Method |
ANCOVA | ||||||||||||||||||
Confidence interval |
|||||||||||||||||||
level |
90% | ||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||
lower limit |
-2.03 | ||||||||||||||||||
upper limit |
1.05 |
|
|||||||||||||||||||
End point title |
Change From Baseline in Postbronchodilator Percent-Predicted Forced Expiratory Volume in 1 Second (FEV1) at Week 16 | ||||||||||||||||||
End point description |
FEV1 is the amount of air that can be exhaled in one second. FEV1 was measured by spirometry. A positive change from baseline in FEV1 indicates improvement in lung function. mITT analysis set included subjects who received at least 1 or partial dose of study agent and had at least 1 post-treatment efficacy measurement.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline and WeeK 16
|
||||||||||||||||||
|
|||||||||||||||||||
Notes [3] - Here "N" signifies number of subjects analysed for this endpoint. [4] - Here "N" signifies number of subjects analysed for this endpoint. |
|||||||||||||||||||
Statistical analysis title |
Statistical Analysis | ||||||||||||||||||
Comparison groups |
CNTO 6785 v Placebo
|
||||||||||||||||||
Number of subjects included in analysis |
185
|
||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||
Analysis type |
superiority | ||||||||||||||||||
P-value |
= 0.286 | ||||||||||||||||||
Method |
ANCOVA | ||||||||||||||||||
Confidence interval |
|||||||||||||||||||
level |
90% | ||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||
lower limit |
-2.57 | ||||||||||||||||||
upper limit |
0.551 |
|
|||||||||||||||||||
End point title |
Change from Baseline in Use of Rescue Medication at Week 16 | ||||||||||||||||||
End point description |
Rescue medication is a relief medication for chronic obstructive pulmonary disease symptoms. example; when subjects feel breathless, chest tight, or frequent cough. The reduction of number of the occasions indicates disease improvement with less symptoms. mITT analysis set included subjects who received at least 1 or partial dose of study agent and had at least 1 post-treatment efficacy measurement.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline and Week 16
|
||||||||||||||||||
|
|||||||||||||||||||
Notes [5] - Here "N" signifies number of subjects analysed for this endpoint. [6] - Here "N" signifies number of subjects analysed for this endpoint. |
|||||||||||||||||||
Statistical analysis title |
Statistical Analysis | ||||||||||||||||||
Comparison groups |
Placebo v CNTO 6785
|
||||||||||||||||||
Number of subjects included in analysis |
185
|
||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||
Analysis type |
superiority | ||||||||||||||||||
P-value |
= 0.843 | ||||||||||||||||||
Method |
ANCOVA | ||||||||||||||||||
Confidence interval |
|||||||||||||||||||
level |
90% | ||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||
lower limit |
-0.762 | ||||||||||||||||||
upper limit |
0.971 |
|
|||||||||||||||||||
End point title |
Change from Baseline in Exacerbations of Chronic Pulmonary Disease Tool-Respiratory Symptoms™ (E-RS™) at Week 16 | ||||||||||||||||||
End point description |
E-RS is a 11-item respiratory system scoring algorithm to assess the severity of respiratory symptoms in participants with chronic obstructive pulmonary disease (COPD). Each item has either 5 or 6 response options. Higher score indicates more severe COPD. mITT analysis set included subjects who received at least 1 or partial dose of study agent and had at least 1 post-treatment efficacy measurement.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline and Week 16
|
||||||||||||||||||
|
|||||||||||||||||||
Notes [7] - Here "N" signifies number of subjects analysed for this endpoint. [8] - Here "N" signifies number of subjects analysed for this endpoint. |
|||||||||||||||||||
Statistical analysis title |
Statistical Analysis | ||||||||||||||||||
Comparison groups |
Placebo v CNTO 6785
|
||||||||||||||||||
Number of subjects included in analysis |
185
|
||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||
Analysis type |
superiority | ||||||||||||||||||
P-value |
= 0.953 | ||||||||||||||||||
Method |
ANCOVA | ||||||||||||||||||
Confidence interval |
|||||||||||||||||||
level |
90% | ||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||
lower limit |
-1.077 | ||||||||||||||||||
upper limit |
1.156 |
|
|||||||||||||||||||
End point title |
Change From Baseline in St George's Respiratory Questionnaire for Chronic Obstructive Pulmonary Disease (COPD) Subjects (SGRQ-C) at Week 16 | ||||||||||||||||||
End point description |
SGRQ-C is a 40-item questionnaire designed to measure health impairment in participants with COPD. SGRQ-C is divided into two components: 1) symptoms, 2) activity and impacts. Total SGRQ-C score ranges from 0 (best) and 100 (worst). Higher scores indicate greater health impairment. mITT analysis set included subjects who received at least 1 or partial dose of study agent and had at least 1 post-treatment efficacy measurement.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline and Week 16
|
||||||||||||||||||
|
|||||||||||||||||||
Notes [9] - Here "N" signifies number of subjects analysed for this endpoint. [10] - Here "N" signifies number of subjects analysed for this endpoint. |
|||||||||||||||||||
Statistical analysis title |
Statistical Analysis | ||||||||||||||||||
Comparison groups |
Placebo v CNTO 6785
|
||||||||||||||||||
Number of subjects included in analysis |
179
|
||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||
Analysis type |
superiority | ||||||||||||||||||
P-value |
= 0.922 | ||||||||||||||||||
Method |
ANCOVA | ||||||||||||||||||
Confidence interval |
|||||||||||||||||||
level |
90% | ||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||
lower limit |
-3.246 | ||||||||||||||||||
upper limit |
2.885 |
|
|||||||||||
End point title |
Number of Subjects With Antibodies to CNTO 6785 At Week 24 [11] | ||||||||||
End point description |
The antibodies to CNTO 6785 analysis set was defined as all subjects who received at least a partial dose of CNTO 6785 and had evaluable samples for antibodies to CNTO 6785 assessment.
|
||||||||||
End point type |
Secondary
|
||||||||||
End point timeframe |
Week 24
|
||||||||||
Notes [11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Statistical analysis was not analysed for the outcome measure. |
|||||||||||
|
|||||||||||
Notes [12] - Here "N" signifies number of subjects analysed for this endpoint. |
|||||||||||
No statistical analyses for this end point |
|
||||||||||||||||
End point title |
Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) | |||||||||||||||
End point description |
An AE is any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. An serious adverse events (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The safety analysis set is defined as all subjects who had received at least a partial dose of study agent by the actual treatment received.
|
|||||||||||||||
End point type |
Secondary
|
|||||||||||||||
End point timeframe |
Up to 24 Weeks
|
|||||||||||||||
|
||||||||||||||||
Notes [13] - Here "N" signifies number of subjects analysed for this endpoint. |
||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Up to 24 weeks
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Non-systematic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
16.0
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Placebo was administered by intravenous (IV) infusion (for not less than 30 minutes in duration) at Study Visit 3, Study Visit 5, Study Visit 6, Study Visit 7 and Study Visit 8. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
CNTO 6785
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
CNTO 6785 6 milligram per kilogram (mg/kg) was administered by IV infusion (for not less than 30 minutes in duration) at Study Visit 3, Study Visit 5, Study Visit 6, Study Visit 7 and Study Visit 8. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
15 May 2014 |
This Amendment 1 included the following changes in the protocol: 1) More frequent chemistry tests were added during the study to ensure all potential safety signals were captured timely; 2) Nasal brushing test was added as an optional choice for all non-bronchoscopy subjects to mitigate the potential risk of inadequate nasal epithelial samples if only collected from bronchoscopy subjects; 3) Extended the maximum screening period for tuberculosis screening from 4 weeks to 6 weeks; 4) Extended the maximum screening period for tuberculosis screening from 4 weeks to 6 weeks; 5) Clarified the exclusion criteria regarding previous episodes of chronic obstructive pulmonary disease (COPD) exacerbations; 6) Clarified that post-dose pharmacokinetic (PK) samples would be collected 1 hour after study agent administration; 7) Relieved subject load of unnecessary pre-bronchodilator spirometry test in the bronchoscopy subgroup at visit 9 if the bronchoscopy was performed on another day different from the efficacy evaluation day. The bronchoscopy eligibility was only related to the post-bronchodilator spirometry value; 8) Sampling dates/times for lab samples were captured on the requisition form but not in the electronic case report forms (eCRF); 9) Deleted unnecessary requirement on electrocardiogram (ECG) test; 10) Clarified that details of strata used for primary analysis were provided in the statistical analysis plan (SAP); 11) Physical examination was not analyzed and summarized by descriptive analysis; 12) Further clarified Independent Data Monitoring Committee (IDMC) performance and kept the statement to be consistent with IDMC charter and Specified that 5 percent (%) dextrose would be used either as diluent for CNTO 6785 or the placebo.
|
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |